Literature DB >> 26872958

The Effects of a Brief Acceptance-Based Behavioral Treatment Versus Traditional Cognitive-Behavioral Treatment for Public Speaking Anxiety: An Exploratory Trial Examining Differential Effects on Performance and Neurophysiology.

Lisa H Glassman1, Evan M Forman2, James D Herbert2, Lauren E Bradley2, Elizabeth E Foster2, Meltem Izzetoglu2, Anthony C Ruocco3.   

Abstract

Individuals with public speaking anxiety (PSA) experience fear and avoidance that can cause extreme distress, impaired speaking performance, and associated problems in psychosocial functioning. Most extant interventions for PSA emphasize anxiety reduction rather than enhancing behavioral performance. We compared the efficacy of two brief cognitive-behavioral interventions, a traditional cognitive-behavior treatment (tCBT) and an acceptance-based behavior treatment (ABBT), on public speaking performance and anxiety in a clinical sample of persons with PSA. The effects of treatment on prefrontal brain activation were also examined. Participants (n = 21) were randomized to 90 min of an ABBT or a tCBT intervention. Assessments took place at pre- and post-treatment and included self-rated anxiety and observer-rated performance measures, a behavioral assessment, and prefrontal cortical activity measurements using functional near-infrared spectroscopy (fNIRS). Exploratory results indicated that participants in the ABBT condition experienced greater improvements in observer-rated performance relative to those in the tCBT condition, while those in the tCBT condition experienced greater reductions in subjective anxiety levels. Individuals in the ABBT condition also exhibited a trend toward greater treatment-related reductions in blood volume in the left dorsolateral prefrontal cortex relative to those who received tCBT. Overall, these findings preliminarily suggest that acceptance-based treatments may free more cognitive resources in comparison with tCBT, possibly resulting in greater improvements in objectively rated behavioral performances for ABBT interventions.
© The Author(s) 2016.

Entities:  

Keywords:  ACT/acceptance and commitment therapy; CBT/cognitive-behavior therapy; SAD/social anxiety disorder/social phobia; anxiety/anxiety disorders; brain imaging/neuroimaging

Mesh:

Year:  2016        PMID: 26872958     DOI: 10.1177/0145445516629939

Source DB:  PubMed          Journal:  Behav Modif        ISSN: 0145-4455


  6 in total

1.  The codesign of an interdisciplinary team-based intervention regarding initiating palliative care in pediatric oncology.

Authors:  Douglas L Hill; Jennifer K Walter; Jessica A Casas; Concetta DiDomenico; Julia E Szymczak; Chris Feudtner
Journal:  Support Care Cancer       Date:  2018-04-07       Impact factor: 3.603

2.  Improving Behavior Analysts' Public Speaking: Recommendations From Expert Interviews.

Authors:  Megan R Heinicke; Jessica F Juanico; Amber L Valentino; Tyra P Sellers
Journal:  Behav Anal Pract       Date:  2021-12-01

3.  Acceptance and Commitment Coaching for Music Performance Anxiety: Piloting a 6-Week Group Course With Undergraduate Dance and Musical Theatre Students.

Authors:  Sarah E Mahony; David G Juncos; Debbie Winter
Journal:  Front Psychol       Date:  2022-03-18

4.  Acceptance and Commitment Therapy for the Treatment of Music Performance Anxiety: A Pilot Study with Student Vocalists.

Authors:  David G Juncos; Glenn A Heinrichs; Philip Towle; Kiera Duffy; Sebastian M Grand; Matthew C Morgan; Jonathan D Smith; Evan Kalkus
Journal:  Front Psychol       Date:  2017-06-15

5.  Piloting a New Model for Treating Music Performance Anxiety: Training a Singing Teacher to Use Acceptance and Commitment Coaching With a Student.

Authors:  Teresa A Shaw; David G Juncos; Debbie Winter
Journal:  Front Psychol       Date:  2020-05-28

6.  Quantification of brainstem norepinephrine relative to vocal impairment and anxiety in the Pink1-/- rat model of Parkinson disease.

Authors:  Jesse D Hoffmeister; Cynthia A Kelm-Nelson; Michelle R Ciucci
Journal:  Behav Brain Res       Date:  2021-08-04       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.